- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunotherapy success, pioneering next-gen personalized treatment approaches, supported by the AI-powered Lunit SCOPE suiteSEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, California, from April 5 to 10..

-Lunit的AACR 2024演讲聚焦HER2突变见解和CNTN4在免疫治疗成功中的作用，开创了下一代个性化治疗方法，由人工智能支持的Lunit SCOPE suiteSEOUL，韩国，2024年4月1日/PRNewswire/--Lunit（KRX:328130.KQ）支持，它是一家领先的人工智能癌症诊断和治疗解决方案提供商，今天宣布将于4月5日至10日在加利福尼亚州圣地亚哥举行的美国癌症研究协会（AACR）2024年年会上介绍七项研究。。

Continue Reading

继续阅读

Lunit to Showcase 7 Studies at AACR 2024

Lunit将在2024年AACR上展示7项研究

In a poster presentation, Lunit's AI-powered HER2 analyzer, Lunit SCOPE HER2's precision shines through its analysis of 194,259 pan-cancer samples, correlating different ERBB2 mutations with changes in HER2 protein expression. This AI-powered assessment successfully identified key mutation-expression correlations, particularly focusing on exon 20 insertions (ex20ins) and S310x mutations across a variety of cancers, including NSCLC, urothelial, and breast cancers..

在Lunit的AI-powered HER2分析仪的海报演示中，Lunit SCOPE HER2的精确度通过对194259个泛癌样本的分析而大放异彩，将不同的ERBB2突变与HER2蛋白表达的变化联系起来。这项人工智能支持的评估成功地确定了关键的突变表达相关性，特别是针对多种癌症（包括NSCLC，尿路上皮癌和乳腺癌）的外显子20插入（ex20ins）和S310x突变。。

Through detailed HER2 intensity examination, the AI analysis highlighted that, among ERBB2-mutated cases with HER2 IHC images, a higher proportion of HER2 3+ tumor cells was observed in S310x and ex20ins cases compared to others. Similarly, high HER2 expression was observed in both S301x and ex20ins cases compared to other mutation cases.

通过详细的HER2强度检查，AI分析强调，在具有HER2 IHC图像的ERBB2突变病例中，与其他病例相比，在S310x和ex20ins病例中观察到的HER2 3+肿瘤细胞比例更高。同样，与其他突变病例相比，在S301x和ex20ins病例中均观察到高HER2表达。

The findings suggest that understanding these mutation-expression relationships could improve the prediction of treatment responses, enabling a step forward in the development of more personalized and precise therapeutic strategies for cancer patients with ERBB2 mutations. The study also indicates the potential of AI in enhancing the precision of cancer treatment through the identification of genetic alterations that influence protein levels..

研究结果表明，了解这些突变-表达关系可以改善对治疗反应的预测，从而为患有ERBB2突变的癌症患者开发更个性化和更精确的治疗策略迈出了一步。该研究还表明，人工智能通过鉴定影响蛋白质水平的遗传改变，在提高癌症治疗精度方面具有潜力。。

In a collaborative study with Genome & Company, a clinical-stage biotechnology specializes in anti-cancer therapeutic development, Lunit leveraged its AI-powered immunohistochemistry (IHC) analyzer to investigate the expression of Contactin-4 (CNTN4) and its relationship with PD-L1 across 18 types of cancers.

在与Genome＆Company（一家专门从事抗癌治疗开发的临床阶段生物技术公司）的一项合作研究中，Lunit利用其AI免疫组织化学（IHC）分析仪研究了Contactin-4（CNTN4）的表达及其与PD-L1的关系。18种癌症。

CNTN4, which is mainly expressed in tumor cells, is known to reduce T-cell activation and responsiveness to tumors.The analysis of 795 pan-cancer tissue samples revealed an important inverse correlation between CNTN4 expression and PD-L1 levels. When PD-L1 intensity was ≥ 30%, 50%, 75%, and 90%, CNTN4 was observed in 42.4% (337/795), 25.5% (203/795), 11.4% (91/795), and 5.2% (41/795) of cases, respectively.

已知主要在肿瘤细胞中表达的CNTN4会降低T细胞的活化和对肿瘤的反应性。对795个泛癌组织样本的分析显示，CNTN4表达与PD-L1水平之间存在重要的负相关。当PD-L1强度≥30%，50%，75%和90%时，CNTN4的发生率分别为42.4%（337/795），25.5%（203/795），11.4%（91/795）和5.2%（41/795）。

This insight positions CNTN4 as a promising target for immunotherapy, particularly in cancers that exhibit low PD-L1 expression.Another study conducted with Genome & Company focused on the correlation between the efficacy of pembrolizumab treatment and CNTN4 expression in gastric cancer patients. This study categorized patients based on CNTN4 and PD-L1 expression levels.

这一见解将CNTN4定位为免疫治疗的有希望的靶标，特别是在表现出低PD-L1表达的癌症中。与Genome＆Company进行的另一项研究侧重于pembrolizumab治疗效果与胃癌患者CNTN4表达之间的相关性。这项研究根据CNTN4和PD-L1表达水平对患者进行了分类。

The results indicated that patients with low CNTN4 expression and high PD-L1 levels were more likely to respond favorably to pembrolizumab, showing a 64.3% objective response rate (ORR). Conversely, patients exhibiting both high CNTN4 and PD-L1 expression demonstrated a 0% ORR, with non-responders presenting lower PD-L1 expression and higher CNTN4 levels compared to responders.

结果表明，低CNTN4表达和高PD-L1水平的患者更有可能对pembrolizumab产生有利反应，客观缓解率（ORR）为64.3%。相反，同时表现出高CNTN4和PD-L1表达的患者表现出0%的ORR，与应答者相比，无应答者表现出较低的PD-L1表达和较高的CNTN4水平。

These findings not only highlight CNTN4's potential as a predictive biomarker for immunotherapy response but also underscore the pivotal role of AI-powered analytics in identifying novel biomarkers.'We are excited to present our groundbreaking studies at AACR 2024, illustrating the profound impact of the Lunit SCOPE suite.

这些发现不仅突出了CNTN4作为免疫治疗反应的预测性生物标志物的潜力，而且强调了人工智能分析在识别新型生物标志物方面的关键作用。”我们很高兴在AACR 2024上展示我们的开创性研究，说明Lunit SCOPE套件的深远影响。

'Pan-Cancer analysis of the influence of ERBB2 alteration on HER2 expression' (4640/16, Section 26, April 9, 9:00 AM - 12:30 PM)

“ERBB2改变对HER2表达影响的泛癌分析”（4640/16，第26节，4月9日，上午9:00-下午12:30）

'Association of artificial intelligence (AI)-based HER2 scoring with clinical outcomes to first-line trastuzumab plus chemotherapy in HER2-positive metastatic gastric cancer (mGC)' (2484/1, Section 43, April 8, 9:00 AM - 12:30 PM)

“基于人工智能（AI）的HER2评分与HER2阳性转移性胃癌（mGC）一线曲妥珠单抗加化疗的临床结果的关联”（2484/1，第43节，4月8日，上午9:00-下午12:30）

'Assessment of CNTN4 expression and its association with PD-L1 across 18 various cancers using an artificial intelligence-powered immunohistochemistry analyzer' (553/6, Section 23, April 7, 1:30 PM - 5:00 PM)

“使用人工智能免疫组织化学分析仪评估18种癌症中CNTN4的表达及其与PD-L1的关系”（553/6，第23节，4月7日下午1:30至5:00）

'Association between the CNTN4 expression and responsiveness to pembrolizumab in gastric cancer' (7522/10, Section 42, April 10, 9:00 AM - 12:30 PM)

“CNTN4表达与胃癌对pembrolizumab反应性之间的关联”（7522/10，第42节，4月10日，上午9:00-下午12:30）

'Artificial intelligence (AI)-based multi-modal approach using H&E and CT image for predicting treatment response of immune checkpoint inhibitor (ICI) in non-small cell lung cancer (NSCLC)' (4170/25, Section 8, April 9, 9:00 AM - 12:30 PM)

“基于人工智能（AI）的多模式方法，使用H＆E和CT图像预测免疫检查点抑制剂（ICI）在非小细胞肺癌（NSCLC）中的治疗反应”（4170/25，第8节，4月9日，上午9:00至下午12:30）

'Artificial intelligence-powered analysis of tumor-stroma ratio and fibroblast density as prognostic indicators in colorectal cancer' (276/7, Section 11, April 7, 1:30 PM - 5:00 PM)

“人工智能支持的肿瘤基质比和成纤维细胞密度分析作为结直肠癌的预后指标”（276/7，第11节，4月7日，下午1:30-下午5:00）

'Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a prognostic biomarker for pembrolizumab plus chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma' (7658/19, Section 46, April 10, 9:00 AM - 12:30 PM)

“人工智能支持的肿瘤浸润淋巴细胞空间分析作为pembrolizumab联合化疗治疗复发或转移性头颈部鳞状细胞癌的预后生物标志物”（7658/19，第46节，4月10日上午9:00-下午12:30）

About LunitFounded in 2013, Lunit is a deep learning-based medical AI company on a mission to conquer cancer. We are committed to harnessing AI to ensure accurate diagnosis and optimal treatment for each cancer patient using AI-powered medical image analytics and AI biomarkers.As a medical AI company grounded on clinical evidence, our findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, and global conferences, including ASCO and RSNA.After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries.

关于Lunit成立于2013年，Lunit是一家基于深度学习的医疗AI公司，其使命是征服癌症。我们致力于利用AI，使用AI支持的医学图像分析和AI生物标志物，确保每位癌症患者的准确诊断和最佳治疗。作为一家基于临床证据的医学人工智能公司，我们的研究结果发表在主要的同行评审期刊上，如《临床肿瘤学杂志》和《柳叶刀数字健康》，以及包括ASCO和RSNA在内的全球会议上。在获得FDA许可和CE标志后，我们的旗舰Lunit INSIGHT套件已在40多个国家的大约3000多家医院和医疗机构中临床使用。

Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io.About Lunit SCOPELunit SCOPE is a suite of AI-powered software that analyzes tissue slide images for digital pathology and AI biomarker development, aiming to optimize workflow and facilitate more accurate and predictive clinical data for clinicians and researchers.Lunit SCOPE platform offers multiple AI-powered tissue analysis products and assays that can streamline digital pathology workflow and diagnostics and enhance the drug development process.Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information.

Lunit总部位于韩国首尔，在全球设有办事处和代表。有关更多信息，请访问lunit.io.About lunit SCOPE lunit SCOPE是一套AI驱动的软件，用于分析组织载玻片图像以进行数字病理学和AI生物标志物开发，旨在优化工作流程，并为临床医生和研究人员提供更准确和预测性的临床数据。Lunit SCOPE平台提供多种AI支持的组织分析产品和分析方法，可以简化数字病理工作流程和诊断，并增强药物开发过程。Lunit SCOPE IO基于H＆E分析分析肿瘤微环境（TME），并提供基于AI的预测性临床结果信息。

In addition, AI-driven Immunohistochemistry (IHC) slide analysis services are offered through products such as Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.SOURCE Lunit.

此外，通过Lunit SCOPE PD-L1，Lunit SCOPE HER2，Lunit SCOPE ER/PR等产品提供AI驱动的免疫组织化学（IHC）幻灯片分析服务。来源Lunit。